The Maharashtra Food and Drug Administration (FDA) will investigate protein powders, nutritional supplements and meal-replacement products over their quality, composition, packaging information and health-related claims, according to a report by Navbharat Times – Mumbai.
The inspection drive will examine whether these products contain the ingredients and quantities stated on their labels and whether manufacturers are complying with the quality standards applicable to the relevant product categories. Authorities will also assess whether the claims made to consumers match the actual nutritional value and contents of the products.
The action is being led by IAS officer Tukaram Mundhe, who heads the Maharashtra FDA. The department has previously taken action against adulteration in food products and milk, and is now turning greater attention to supplements that have become widely available to urban consumers.
Protein powders and nutritional supplements are increasingly marketed for bodybuilding, weight loss, weight gain and muscle development. The products are also sometimes sold or promoted as substitutes for meals. The FDA’s planned scrutiny will cover products sold for these purposes, along with related nutritional items.
The investigation will focus on food-safety compliance and the accuracy of product information. This includes checking the ingredients used, nutritional values shown on packaging and claims made by manufacturers or sellers. The department has stated that consumers must receive correct information about the contents and nutritional value of such products.
The report also cited dietitian Mukta Gaikwad, who said protein powder alone cannot replace a complete diet. A balanced diet is needed to provide protein and other nutrients, while inadequate intake of nutritious food can weaken the immune system and increase the risk of infection, according to the report.
Nutrition supplements may be recommended by dietitians or medical experts for specific medical needs or during treatment for certain conditions. However, many of these products are available without a prescription, making them accessible for unsupervised use. The FDA’s proposed checks will therefore examine both the products and the information through which they are marketed to consumers.
The department has warned that legal action may follow if manufacturers or products are found to be violating applicable rules. The report did not specify the number of products to be tested, the locations of inspections or a completion timeline for the investigation.
